Thu.Oct 24, 2024

article thumbnail

Opinion: ‘Do no harm’ is hurting 400 million long Covid patients worldwide

STAT

Imagine, for a moment, that you wake up one morning with a debilitating illness that won’t let go. Weeks and months pass, but the crushing fatigue, constant headaches, and aching muscles remain. You can’t think straight. Simply showering or doing the dishes leaves you floored for days at a time, and the unpredictable symptoms — shortness of breath, dizziness, a racing heart — ebb and flow without warning.

364
364
article thumbnail

Why pharma megamergers may become a relic of the past

PharmaVoice

Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.

147
147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drinking is cheaper than it’s been in decades. Lobbyists are fighting to keep it that way

STAT

For years, it has been a reliable way to cut back on the consumption of cigarettes and sugary drinks: raise taxes on them. So it might seem an obvious tactic to apply to alcohol, which contributes to untold injuries, diseases and deaths in the United States each year. That’s the thinking of advocates and state legislators across the country, who also see it as a way to pull in more revenue.

Hospitals 358
article thumbnail

AstraZeneca ‘said it could cut UK jobs’ if biodiversity drug levy is introduced

The Guardian - Pharmaceutical Industry

Biotech giant’s alleged comments come as world leaders at Cop16 discuss how to share benefits from genetic code discoveries fairly AstraZeneca has said it may cut jobs at its UK operation if the government enforces a global push to make companies share profits derived from nature’s genetic codes, multiple sources have told the Guardian. The alleged comments from the company came amid a concerted lobbying push by the pharmaceutical industry against the profit-sharing measures.

115
115
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study

STAT

Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes, an analysis of medical records found, supporting the case for further research of the blockbuster GLP-1 drug in neurodegenerative diseases. Among the over 1 million people with diabetes whose records were included in the study, the overall risk of developing Alzheimer’s was already very low.

Diabetes 355
article thumbnail

Intellia data spark debate about CRISPR drug’s potential

BioPharma Dive

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its commercial outlook.

109
109

More Trending

article thumbnail

UK launches scheme to boost dementia trial participation

pharmaphorum

UK scheme to tackle "historically low" numbers of people taking part in dementia trials launches with £20m in government funding

119
119
article thumbnail

CDC testing suggests Missouri did not see a cluster of bird flu cases

STAT

Blood testing conducted by the Centers for Disease Control and Prevention has confirmed that one person in Missouri with no known exposure to cattle or poultry contracted H5N1 bird flu in August, and a household contact of the individual may also have been infected. But five health workers who went on to develop influenza-like symptoms after caring for the confirmed case were not infected with the virus.

298
298
article thumbnail

Hyntelo: AI solutions for improved customer engagement

pharmaphorum

Hyntelo offers cutting-edge AI solutions like GenAI for enhanced customer engagement. Learn how Hyntelo integrates as a Veeva AI Partner.

104
104
article thumbnail

STAT+: General Catalyst raises $8 billion fund with $750 million for health care bets

STAT

The venture capital giant General Catalyst has raised an $8 billion fund with $750 million set aside for health care investments as its acquisition of an Ohio safety net hospital undergoes regulatory review. Fund XII consists of $4.5 billion for funds dedicated to seed and growth equity, $1.5 billion for creating new companies, and $2 billion of “separately managed accounts,” the firm said.

Hospitals 269
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

NICE recommendation for new Alexion PNH treatment

Pharma Times

danicopan shown to improve haemoglobin levels and reduce anaemia

135
135
article thumbnail

STAT+: Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores

STAT

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, the personalized, BCMA-directed CAR-T therapy for multiple myeloma being developed under a pa

283
283
article thumbnail

WhatsApp lands Moderna in hot water with PMCPA

pharmaphorum

WhatsApp message earns Moderna a reprimand under the ABPI Code, with Novo Nordisk, Otsuka, AstraZeneca and Daiichi Sankyo also breaching the rules

96
article thumbnail

STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line

STAT

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. The EMBARK Phase 3 study for Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy,  was published this month  in Nature Medicine. The paper largely reiterates what’s already known about the negative study — Elevidys failed to achieve its primary endpoint of improving ov

274
274
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

The GP Awards shortlist: Nazir Hussain, specialist respiratory pharmacist

The Pharmacist

We caught up with the Pharmacist/Pharmacy Team of the Year Award shortlist ahead of this year’s General Practice Awards ceremony to be held on 6 December at the Novotel London West. Nazir Hussain, specialist respiratory pharmacist, is making significant strides in improving respiratory care in the community with a ‘one-stop’ respiratory clinic. Working with the […] The post The GP Awards shortlist: Nazir Hussain, specialist respiratory pharmacist appeared first on The Pharmacist.

90
article thumbnail

Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions

STAT

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F.

272
272
article thumbnail

NICE rejects second Alzheimer’s drug but opportunity remains for decision change: GlobalData

Express Pharma

Following the news that the National Institute for Health and Care Excellence (NICE) is not recommending Eli Lilly’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla (donanemab) on the NHS following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD); Philippa Salter, Managing Neurology Analyst at GlobalData, offers her view: “While disappointing for the many pat

95
article thumbnail

The war against alcohol taxes

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning! If you aren’t already subscribed to DC Diagnosis , the newsletter from our amazing reporters down in DC, what are you doing? Have some coffee Pharmalot -style, then get on that.

258
258
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Lundbeck planning for four novel drugs in phase 3 in 2026

pharmaphorum

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.

87
article thumbnail

Health AI startups: How long do they take to hit $10 million in sales

STAT

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Are health AI businesses zooming? In a new report , Bessemer Venture Partners unpacks early insights about the prospects for artificial intelligence software services businesses it sees as a new category in the broader health tech ecosystem.

248
248
article thumbnail

NICE rules newly-approved Alzheimer’s-slowing drug too costly for NHS

The Pharmacist

The UK medicines regulator has approved a new treatment that can slow Alzheimer’s disease progression, but NICE has said it is too costly for the NHS. Donanemab, produced by Eli Lilly, is used to treat mild cognitive impairment or mild dementia via a monthly infusion and it requires ‘intensive monitoring for serious side effects’. NICE […] The post NICE rules newly-approved Alzheimer’s-slowing drug too costly for NHS appeared first on The Pharmacist.

86
article thumbnail

STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more

STAT

Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for their breakfast on the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is maple bourbon. Yes, this is for real.

Immunity 258
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Mankind Pharma completes acquisition of BSV

Express Pharma

This acquisition strengthens Mankind’s leadership in the fertility drug market and grants access to BSV’s R&D-driven biologics and niche products, further solidifying its presence in high-entry barrier segments Mankind Pharma has completed the transaction to acquire 100 per cent stake in Bharat Serums and Vaccines Limited (BSV), for a purchase consideration of Rs 13,768 crores.

article thumbnail

Opinion: STAT+: Four leading biopharma executives weigh the 2024 election

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. Read an excerpt from each below. “ What Sandoz CEO Richard Saynor is thinking about the 2024 elections ” With all eyes currently on the upcoming U.S. elections, it’s easy to forget that this

article thumbnail

No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows

Drug Channels

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.

78
article thumbnail

The GP Awards shortlist: Nazir Hussain, specialist respiratory pharmacist

The Pharmacist

We caught up with the Pharmacist/Pharmacy Team of the Year Award shortlist ahead of this year’s General Practice Awards ceremony to be held on 6 December at the Novotel London West. Nazir Hussain, specialist respiratory pharmacist, is making significant strides in improving respiratory care in the community with a ‘one-stop’ respiratory clinic. Working with the […] The post The GP Awards shortlist: Nazir Hussain, specialist respiratory pharmacist appeared first on The Pharmacist.

70
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

How to Manage Regulatory Challenges in Generic Drugs

Drug Patent Watch

The generic drug industry faces significant regulatory challenges that can impact the quality and safety of these life-saving medications. With the majority of generic drugs manufactured overseas, ensuring compliance with regulatory standards is crucial. This article delves into the complexities of generic drug regulation, highlighting the challenges faced by the U.S.

70
article thumbnail

Lyell, in search of a turnaround, to buy cell therapy startup ImmPact

BioPharma Dive

The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell has opted to end development of two current pipeline programs.

78
article thumbnail

Merck acquires cancer startup in a deal worth up to $1.3 billion

Outsourcing Pharma

Merckâs acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes.

82
article thumbnail

GPCR drugmaker Septerna amasses $288M in IPO

BioPharma Dive

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.

73
article thumbnail

The Dangers Surrounding Bits and Bytes

Pharmaceutical Commerce

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, forecasts how cyber threats could potentially evolve over the next decade.

64